Research led by Professor Hai-Ling Margaret Cheng (BME) opens the door to earlier treatment and better outcomes ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

The message is that an early decrease in eGFR with finerenone should not lead to stopping the medication, say HF experts.

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing ...

The mechanism behind β-blockers' potential in improving diastolic function in patients with HFPEF is believed to be associated with the drugs' negative chronotropic and negative inotropic ...

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products ...

Faun1083 has demonstrated positive in-vivo efficacy in multiple preclinical animal models, including rat sugen hypoxia and ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

While HFpEF currently doesn’t have any approved ... While Tectonic Therapeutic is targeting a significant unmet medical need with a potentially best-in-class therapy, it faces the same risks ...